Focal Therapy in Kidney Cancer by Malki, Manar & Emara, Amr
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
125,000 140M
TOP 1%154
5,000
Provisional chapter
Focal Therapy in Kidney Cancer
Manar Malki and Amr Emara
Additional information is available at the end of the chapter
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
anar  alki and r E ara
Additional information is available at the end of the chapter
Abstract
The widespread use of imaging has led to an unprecedented increase in the diagnosis of 
small renal masses. Incidence rate has increased worldwide and most notable in older 
population (more than 75 years). There has been an evident revolution in the manage-
ment of patients with small renal masses. Treatment strategies include active surveil-
lance, partial nephrectomy, radical nephrectomy and focal ablative therapies. Nephron 
sparing surgery for small renal tumours offers comparable cancer-specific survival and 
better overall survival when compared to radical nephrectomy. Nevertheless, complica-
tions related to extirpative surgery must be taken into consideration. Thermal ablative 
therapies were developed in an attempt to provide a reproducible treatment option with 
low risk of complications. Energy based renal ablation therapy offers treatment flexibil-
ity, technically less challenging procedure with acceptable oncological outcomes.
Keywords: small renal tumours, kidney cancer, cryoablation, radiofrequency ablation, 
microwave ablation
1. Introduction
A number of population based studies reported an increase in the incidence of diagnosed 
small renal masses ≤4 cm [1–2]. Nephron sparing treatment remains the recommended treat-
ment for cT1a renal masses, especially in young healthy patients. Partial nephrectomy carries 
the same oncological outcomes to radical nephrectomy in treating patients with cT1a renal 
masses [3–6].
Over the last 2 decades, thermal ablation has emerged as alternative treatment option for the 
management of patients with renal masses <3 cm in size. Focal ablative treatment is associated 
with fewer complications and less morbidity. It offers a viable treatment alternative especially 
in patients whom might not be medically suitable for extirpative surgery.
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Focal ablative treatment offers flexibility with treatment’s approach. Tumours could be treated 
laparoscopically, percutaneously or less often open approach. The American Urological 
Association recommends percutaneous access over surgical approach whenever is feasible [8].
Focal ablative therapy is well tolerated and technically less challenging. Hilar dissection and 
clamping is not a prerequisite in focal ablative therapy. Renal parenchymal loss is minimal 
following ablative therapy.
2. Cryoablation
2.1. Mode of action
The therapeutic principle of cryotherapy treatment is selective destruction of tumour cells 
with minimal injury to the surrounding tissue. Argon and helium are the most commonly 
used freezing agents. New cryotherapy systems use the Joule-Thomson principle to generate 
lethal temperature down to −187.5°C. Very low temperature causes direct cellular damage 
during freezing phase and indirect reperfusion injury during the thawing phase.
Cellular changes secondary to cryotherapy treatment could be summarised in four main 
stages:
• Formation of extracellular ice crystals leading to hyperosmolar extracellular environment 
and cells shrinkage
• Formation if intracellular ice crystals causing cells damage
• Metabolic activity stops at −40°C
• Thrombosis and micro capillary damage leading to necrosis
To achieve the described cellular changes, it is essential to achieve the following aspects of the 
cryotherapy treatment [7].
2.1.1. Target treatment temperature
It is understood that irreversible tissue damage is achieved when cells are exposed to tempera-
ture between −20 and −50°C. Different structures of the kidney react differently to freezing 
temperatures. This behaviour is largely related to collagen and elastin content. Renal collecting 
system and renal vasculature tolerate cryoablation without real long term injuries. However, 
renal parenchyma is usually destroyed at −19.4°C. It is recommended to achieve temperature 
of −40°C or below to ensure killing tumour cells. Thermosensors are usually placed at the 
edge of the tumour to ensure adequate treatment temperature for the area of interest.
2.1.2. Double freeze-thaw cycle
The standard of care during renal tumour cryoablation is double freeze-thaw cycle. This 
concept has been established after an experiment on 16 female dogs. More adequate area of 
Evolving Trends in Kidney Cancer2
treatment and liquefaction was achieved following two freeze-thaw cycles compared to dogs 
who had only one treatment cycle.
2.1.3. Satisfactory ablation area
It is recommended to perform cryoablation treatment for renal tumours under real-time 
imaging. The operator should aim for treatment area of 10 mm beyond the margin of tumour 
to ensure adequate treatment temperatures.
2.1.4. Duration of treatment
The duration of treatment should be balanced against risk of suboptimal treatment with short 
cycles or risk of tissue fracture and bleeding with long treatment. The optimal duration of 
freezing cycles is not well described in the literature. Two active cycles with initial freeze cycle 
of 8–10 min and a second freeze cycle of 6–8 min is considered the optimal.
2.2. Guidelines
The European Association of Urology guidelines state that, due to lack of high quality data, no 
recommendation can be made on cryoablation and radiofrequency ablation [9]. The American 
Urological Association (AUA) recently released its guidelines for management of patients 
diagnosed with small renal masses [8]. Focal ablative therapy should be offered as an option 
rather than standard treatment in high risk patients [8, 9].
Cryotherapy treatment offers a viable alternative to surgery especially in following clinical 
circumstances:
• Patients with multiple comorbidities
• Elderly patients
• Patients with multiple/bilateral renal tumours
• Patients with impaired renal function
Cryotherapy is usually recommended for small renal tumours (<3 cm in size). Cystic renal 
masses and hilar masses represent relative contraindications for cryotherapy treatment. 
Untreated coagulopathy is an absolute contraindication for cryotherapy treatment.
2.3. Modality of treatment
Cryotherapy treatment can be delivered percutaneously, laparoscopically or less often with 
open surgical approach.
Laparoscopic mobilisation of the kidney and accurate dissection of the tumour might provide 
an excellent exposure of the tumour. It allows treating anteriorly located tumours safely, thus 
avoiding injury to surrounding structures. Laparoscopic approach allows real time monitor-
ing of ice-ball formation in cryotherapy treatment and confirmation of probes positioning.
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Location of the tumour and surgical expertise would normally mandate the approach of laparo-
scopic cryoablation (transperitoneal or retroperitoneal). Standard three ports technique is used. 
Gerota fascia is incised. The kidney is mobilised and tumour is identified. The overlaying and 
surrounding fat might be excised to allow accurate assessment during the treatment. Histological 
confirmation with 18-gauge biopsy needle is advocated if no prior biopsies have been taken.
Cryoprobes are inserted percutaneously under direct vision. Laparoscopic ultrasonography 
is used to confirm the location of the probes and the margins of the tumour. Treatment is 
delivered with double freeze-thaw cycle. Cryoprobes are removed. Low pressure check is 
performed to check for any post-interventional bleeding.
Percutaneous cryotherapy can be performed as an outpatient procedure under conscious 
sedation or general anaesthesia. It might offer an advantage to laparoscopic approach espe-
cially patients requiring multiple procedures as in Von Hippel-Lindau (VHL) disease. The 
American Urological Association (AUA) recommends a renal biopsy prior to ablation to pro-
vide pathological diagnosis and minimise over treatment of benign conditions [8].
Following anaesthetic induction patient is positioned in the prone or flank position. Lesion 
is characterised following the administration of intravenous contrast depending on imaging 
technique (iodinated or gadolinium contrast). Tumour is localised with finder needle (20-
gauge). A representative biopsy is taken with 18-gauge Try-Cut core biopsy needle under 
CT/MRI guidance. Positioning of cryoprobes and prongs are confirmed with repeat imaging. 
Cryotherapy treatment is carried out achieving the standard of care principles. Once treat-
ment is completed; cryoprobes are removed. Post treatment imaging is performed to check 
treatment adequacy and evaluate for potential bleeding.
2.4. Follow-up and oncological outcomes
The absence of histological evidence for treatment success remains an inherent criticism for 
focal ablative therapy. The interpretation of a routine biopsy following cryotherapy treat-
ment is highly controversial. Therefore, the determination of treatment success is solely reli-
ant on radiological evaluation. Radiological evaluation of treatment success is interpreted 
by complete loss of contrast enactment of follow-up CT or MRI scan. Treated renal lesion 
is expected to shrink by >50% in size within the first year following cryotherapy treatment. 
Most of urological institutions recommend first CT scan or MRI scan with 3–6 months post 
cryotherapy treatment. Currently, there is no consensus on surveillance after RCC treatment. 
A six monthly CT scan is usually recommended within the first year of follow-up. Annual 
CT scan is recommended thereafter if favourable response to treatment has been established.
Selective post cryotherapy treatment biopsy should be sought in the following situations:
• If a lesion demonstrates persistent contrast enhancement following treatment (Incomplete 
treatment).
• If a lesion demonstrates enlargement following cryotherapy treatment and or new contrast 
enhancement (Local tumour recurrence or progression).
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2.5. Treatment outcomes
Currently, there are no RCTs comparing treatment outcomes of PN with focal ablative thera-
pies for small renal masses. The CONSERVE trial was a feasibility multicentre RCT attempted 
to compare PN with CA and RFA. The study was however unable to recruit the desired num-
ber of patients [10].
Rai and colleagues [11] performed recent meta-analysis in which they compared outcomes 
of partial nephrectomy and cryoablation. This study highlighted significantly lower recur-
rences rates following RAPN. The overall recurrence rates in the CA cohort were 11.5% 
compared with 0% in the RAPN cohort. Similar results were concluded from met analysis 
of 13 studies comparing laparoscopic and RAPN with LCA; 9.4 vs. 0.4% respectively [12]. 
The analysis suggested LCA might be associated with improved peri-operative outcomes. 
These meta-analyses found that impact on oncological survival and mortality outcomes was 
profound. These results should be carefully evaluated, as it might reflect the short onco-
logical follow-up [11, 12]. A retrospective review of more than 800 patients reviewed the 
intermediate oncological outcomes of LCA. The 5 and 10 year disease survival was reported 
at 90.4 and 80.0% respectively; however the 5- and 10-year overall survival in the study was 
83.2 and 64.4% [13].
2.6. Complications
Cryotherapy is relatively safe procedure with low risk profile. Percutaneous and laparo-
scopic cryotherapy have similar overall complication rates [14, 15]. As one might expect, the 
length of in hospital stay following percutaneous cryoablation is shorter when compared to 
laparoscopic cryoablation [15, 16]. A recent systematic review reported the overall rates of 
complications following cryoablation therapy range from 7.8 to 20%. Zargar and colleagues 
[17] found that complications rate for percutaneous cryoablation are lower than laparoscopic 
cryoablation (2.8–12.9% vs. 15–20% respectively). The incidence of major urological complica-
tions following cryotherapy is 4.9% (3.3–7.4%).
Post-operative haemorrhage is the common reported complication. Other reported compli-
cations are ureteric injury and obstruction, peri-renal abscess and haematuria. Other minor 
non-urological complications include pain and paraesthesia at the probe site, urinary tract 
infections and self-limited haematuria. Reintervention following cryoablation therapy is 
reported at 2.6%.
3. High temperature ablative techniques
Cancer cells are very sensitive to both very high and low temperature. Radiofrequency and 
microwave energies use the concept of high temperature (above 55°C). Thermal ablation 
causes denaturation of cellular proteins and vascular necrosis of tumour cells resulting in 
instantaneous cellular death.
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3.1. Radiofrequency ablation
3.1.1. Mode of action
Electric current passes through radiofrequency ablation (RFA) probe/electrode into tumour 
creating closed loop circuit with a generator and grounding pads. The current triggers disrup-
tion of intracellular ions and friction between molecules producing heat. The electromagnetic 
field generates high temperature typically above 55°C. The generated heat results in cytotoxic 
effect and instantaneous cell death occurring with temperature reaching 60°C [18].
3.1.2. Technique
Small renal masses (≤3 cm) can be treated with single cycle of RFA. However, larger tumours 
(up to 5 cm) might be suitable for treatment using overlapping cycles technique. RFA achieves 
excellent results in treating exophytic and endophytic tumours.
RFA is carried out under general anaesthetic or conscious sedation. Different types of RFA 
electrodes could be used including; single tip, multi-tined expandable electrodes, or a cluster 
tip electrode. RFA electrodes are inserted into the tumour under CT/MRI or ultrasound guid-
ance. Hydro-dissection can be used if the tumour is adjacent to bowel segment.
Once electrodes are positioned; a 12 min cycle is delivered. Some RFA systems use internal 
cooled electrodes to avoid adjacent tissue carbonization. This method might have an impact 
on heat distribution to distant area of the tumour and subsequently might affect the efficacy 
of treatment [19, 20].
3.2. Microwave ablation
3.2.1. Mode of action
Microwave ablation uses the same concept of thermal ablation as RFA technique. Thermal 
ablation results in coagulative necrosis of tumour cells. Microwave ablation uses different 
energy source. It produces an electromagnetic spectrum with frequency of 900–2450 MHz. 
The oscillating microwave field causes polarisation of molecules resulting in increased kinetic 
energy producing heat.
Microwave ablation has several advantages over radiofrequency ablation. It is possible to 
treat larger tumours without the need of overlapping treatments. Microwave ablation does 
not cause charring effect. Skin pads are not required during microwave ablation treatment; 
therefore the risk of skin burns is minimal.
3.2.2. Technique
Two microwave antennae are inserted under CT or ultrasound guidance. A fibre-optic thermal 
sensor inserted at the periphery of the tumour to provide continuous temperature monitoring. It is 
recommended to delivers 3 cycles achieving temperature of 60°C. Each cycle lasts for 20 min [21].
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3.3. Possible side effects of high thermal ablative techniques
• Heat sink effect: kidney is well perfused organ. this may result in unequal distribution of 
the heat particularly close to the larger vessels.
• Thermal injury to neighbouring structures such as bowels, ureter, genitofemoral nerve and 
psoas major muscle.
• Post-ablation syndrome: the syndrome is usually self-limiting. Patients might suffer 
symptoms of low-grade fever (37.5–38.5°C), delayed pain, nausea, vomiting, malaise, and 
myalgia.
• Haematuria and peri-nephric haematoma are usually self-limiting.
• Hyper adrenal crisis is very rare. This might be secondary to adrenal thermal injury.
• Skin burns (mainly with radio-frequency ablation).
• Calyceocutaneous fistulae.
• Infection and abscess formation.
• Acute tubular necrosis and decreases overall renal function [22].
3.4. Oncological efficacy
Few studies have evaluated the short and intermediate oncological outcomes. The technical 
success rate has been reported to be 95.5–98.5%. The average need for repeat treatment is 
thought to be around 3%. Small renal tumours (<3 cm) and exophytic location were indepen-
dent factors for successful treatment. The overall 5 year survival rate was reported between 
65–85% and cancer specific survival rate of 88–97.9% [23–25].
3.5. Monitoring and follow up
Most urological institutions recommend contrast enhanced CT scan at 3 months to evaluate 
treatment success. Follow-up CT scan is suggested every 6 months for the first 2 years. Annual 
CT scan is suggested thereafter for a period up to 7 years.
4. Investigational and experimental treatments
4.1. Laser interstitial thermal therapy (LITT)
This treatment modality is currently being evaluated for treatment of solid tumours including 
brain, pancreatic, breast, thyroid and prostate cancer. LITT utilizes image guided low voltage 
laser probes to deliver heat and destroy target tissue. Optical fibres are inserted directly to the 
target tissue. Laser light delivers heat that is converted to heat. The emitted light energy from 
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laser fibres is absorbed and converted to heat. This would result in thermal destruction of 
the cancer cells [26]. Neodymium: yttrium-aluminium-garnet (Nd:YAG) laser has been used 
to treat small renal tumours. All reports are based on small number of treated patients with 
short follow up [27, 28]. LITT remains an experimental treatment.
4.2. Extracorporeal high-intensity focused ultrasonography (HIFU)
The therapeutic use of the ultrasound to treat cancer was established in the 1970s. The mecha-
nism of HIFU involves mechanical and thermal effects. Some of the acoustic wave is con-
verted to heat once absorbed by the tissue. The thermal phenomenon causes cell death by 
coagulation necrosis once tissue temperature exceeded the 65°C. The mechanical effect causes 
micro-streaming, cavitation and radiation force [29].
HIFU offers completely trackless non-invasive ablative technology. Treatment session can 
be lengthy. Several studies reported incomplete treatment when renal tumours were excised 
following HIFU treatment. Skin burns were reported up to 10% of the patients. Respiratory 
movement and acoustic interference could impede on delivering treatment accurately. Other 
limitations to HIFU treatment include limited focal zone depth and inability to monitor 
treatment progression in real life [30–32]. Recent studies investigated the role of magnetic 
resonance-guided high intensity focused ultrasound. The results are promising, however it 
remains experimental [33, 34].
Laparoscopic HIFU has recently evolved to overcome the challenges related to respiratory 
movements, targeting tumours and acoustic interference.
HIFU is considered to be experimental treatment. It could be considered in some selected 
cases.
5. Conclusion
In conclusion, ablative therapies have emerged as an alternative option to extirpative surgical 
treatment. Percutaneous focal ablative therapies represent a valid treatment option especially 
for high risk patients. Randomised controlled trials are needed to compare treatment out-
comes of PN with focal ablative therapies for small renal masses.
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